Showing 176–200 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Rockwood N, Cerrone M, Barber M, Hill AM, Pozniak AL
…TB), in HIV co-infected patients on currently utilized cART regimens or in paediatric populations. An important advantage of rifabutin is that compared to the dose adjustments required with rifampicin, it can be co-administered with the integrase strand transfer inhibitors ralteg…
Chuang YM, Dutta NK, Gordy JT, Campodónico VL, Pinn ML, et al.
The lengthy and complicated current regimen required to treat drug-susceptible tuberculosis (TB) reflects the ability of Mycobacterium tuberculosis (Mtb) to persist in host tissues. The stringent response pathway, governed by the dual (p)ppGpp synthetase/hydrolase, Rel Mtb , is a…
Chabala C, Turkova A, Thomason MJ, Wobudeya E, Hissar S, et al.
Background Tuberculosis (TB) in children is frequently paucibacillary and non-severe forms of pulmonary TB are common. Evidence for tuberculosis treatment in children is largely extrapolated from adult studies. Trials in adults with smear-negative tuberculosis suggest that treatm…
Pasipanodya JG, Smythe W, Merle CS, Olliaro PL, Deshpande D, et al.
Background In the experimental arm of the OFLOTUB trial, gatifloxacin replaced ethambutol in the standard 4-month regimen for drug-susceptible pulmonary tuberculosis. The study included a nested pharmacokinetic (PK) study. We sought to determine if PK variability played a role in…
Garessus EDG, Mielke H, Gundert-Remy U
…plasma ranged between 0.04 and 0.78 mg/L for the two dosing regimens. We therefore conclude that infant exposure to isoniazid via breast milk after maternal drug intake of highest recommended doses is very low. We expect that such low exposure levels most likely do not cause any …
Adepoju VA, Adelekan A, Etuk V, Onoh M, Olofinbiyi B
…TP providers also self-reported prescribing 23 different TB regimens, including streptomycin, to treat TB. Only 32.4% of providers self-reported using the correct combinations of anti-TB drugs to treat TB. Additionally, 58.3% of providers prescribed the standard 6-month treatment…
Akkerman OW, Duarte R, Tiberi S, Schaaf HS, Lange C, et al.
BACKGROUND: The aim of these clinical standards is to provide guidance on 'best practice´ for diagnosis, treatment and management of drug-susceptible pulmonary TB (PTB). METHODS: A panel of 54 global experts in the field of TB care, public health, microbiology, and pharmacology w…
Jo KW, Kim M, Kim YJ, Lee HK, Kim HK, et al.
No studies have investigated whether discontinuation of ethambutol (EMB) based on the susceptibility to isoniazid and rifampin as determined by the GenoType MTBDR plus assay would be appropriate. We aimed to determine the feasibility of discontinuing EMB before the end of intensi…
Francis J, Zvada SP, Denti P, Hatherill M, Charalambous S, et al.
…ADAC) on rifapentine exposure. Two studies evaluating novel regimens among southern African patients with drug-susceptible pulmonary tuberculosis were included in this analysis. In the RIFAQUIN study, rifapentine was administered in the continuation phase of antituberculosis trea…
Alghamdi WA, Al-Shaer MH, Peloquin CA
The 4-drug regimen of rifampin, isoniazid, pyrazinamide, and ethambutol is an inexpensive, reliable option for treating patients with drug-susceptible tuberculosis (TB). Its efficacy could be further improved by determining the free drug concentrations in plasma, knowing that onl…
Carole D Mitnick, Sc.D, Geraint Davies, B.M., Ph.D
The purpose of this study is to evaluate the potential of high doses of rifampin (RIF) to shorten treatment for tuberculosis (TB) without causing more adverse events. The hypotheses are that higher doses of RIF will result in higher blood concentrations of RIF; higher blood conce…
Morounfolu Olugbosi, MD MSc
…Weeks (24-months) post the start of the following treatment regimens in participants with: Drug Sensitive TB (DS-TB) patients given BPaMZ for 17 Weeks ( or 4 months) vs. Standard HRZE/HR treatment given for 26 weeks (or 6 months) and Drug Resistant TB (DR-TB) patients given BPaMZ…
Lina Davies Forsman, MD, PhD
…ield of TB. This study will evaluate the logistics and dose regimens when clinicians are given the current dose recommendations of the first-line drugs rifampicin, isoniazid and pyrazinamide, as well as the results of the MIPD, for patients with active pulmonary TB.
Olanisun P Adewole, MD, Bolanle A Omotoso, MD
Tuberculosis (TB) is caused by mycobacterial organism. It is the leading infectious disease cause of death globally, with more than 10 million new cases and over 2 million deaths annually. Developing countries bear the greatest brunt of the disease. The long duration of current t…
Michael Hoelscher, Prof, Andreas Diacon, Prof
…el group comparison of 4 arms receiving different treatment regimens: three arms to receive BTZ-043 in different doses within the safe corridor defined in stage 1, compared to one arm receiving Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol as a control. This stage is focusi…
Chunyan Fan, Xiaoli Ye, Chengpeng Wang, Yuqing Wu, Bin Tong, et al.
…omes. Data on study design, participant characteristics, VD regimens, and outcome measures were systematically extracted. Risk ratio (RR) was calculated for dichotomous outcomes, and standardized mean difference (SMD) was used for continuous outcomes. Statistical heterogeneity wa…
S. Richardson, Pamela Vorster, Ronelle Burger, Matthias Rieger
<sec> <title>BACKGROUND</title> Tuberculosis (TB) is the leading cause of death in South Africa. Drug susceptible (DS) TB is effectively treated with a 6-month regimen, but inadequate medication adherence remains an important impediment to containing the spread of the disease and…
Ismaila L. Manneh, Fatoumatta Darboe, Haddijatou Jobe, Binta Sarr Kuyateh, Ousainou Cham, et al.
Background Despite availability of effective treatment regimens for drug-susceptible Tuberculosis (TB), some patients still experience poor treatment outcomes. Currently tools for monitoring treatment outcomes are dependent on detection of mycobacteria in sputum, which are slow, …
A. Sontakke, P. Murarka, Rachana A Sontakke
Abstract Rational Treated PTB patients contribute to the growing global burden of chronic respiratory morbidity. NTEP lack structured care beyond treatment completion, highlighting the need for increased awareness and research efforts to address the long-term needs of TB survivor…
Josephine Amie Koroma, Mariama Mahmoud, Bailah Molleh, Stephen Sevalie, Adrienne K. Chan, et al.
…r age, gender, nutritional status, HIV status and treatment regimens. A p-value of <0.05 was considered statistically significant at 95% confidence level. Results Of the 701 drug-resistant TB patients, 383 (54.6%) were registered in the pre-COVID-19 period, 228 (32.5%) during …
Cross, Gail
…nt remains prolonged despite highly effective antimicrobial regimens, reflecting persistent host-mediated inflammation and tissue damage. Host-directed therapies (HDTs) have emerged as a complementary strategy to improve treatment response by modulating maladaptive immune pathway…
Kuppli Sai Sushma, Devi Madhavi Bhimarasetty, Siva Kumar Lotheti
In March 2016, RNTCP revised its technical and operational guidelines. One of the major additions was introduction of Daily Regimen in the treatment of Drug sensitive TB, started initially among TB-HIV co-infected patients in 2017. The present study was taken up to assess the tre…
Mustafa Singapurwala, Poonam Gupta, Rohit Mishra, Amar Mandil, Swapnil Jain, et al.
The magnitude of TB disease, including drug resistance, is huge and alarming in India, being the highest-burden country. The steps taken during the initial decades after getting independence in 1947 were slower and not very effective which is reflected in the timeline depicting c…
Alfi Nurul Islamiyah, Syarifuddin Syarifuddin, Morsalina Akhsa, Iis Rukmawati, Eni Margayani, et al.
Tuberculosis (TB) remains a significant global health concern, particularly in Indonesia. Ensuring rational TB treatment is crucial for effective disease control and preventing the emergence of drug resistance. This study aimed to evaluate the rationality of TB treatment among ne…
Win Pa Pa Thu, Fei Kean Loh, Ong C
…]. Numerous clinical trials have explored shorter treatment regimens of 2–4 months to enhance adherence for better disease control [5–8].